PHEBRA & CLARITY PHARMACEUTICALS WORK TOGETHER WITH NEW FUNDING FOR RADIOPHARMACEUTICAL THERAPY

Media Release: Sydney, Australia. 14 July, 2016.

PHEBRA & CLARITY PHARMACEUTICALS WORK TOGETHER WITH NEW FUNDING FOR RADIOPHARMACEUTICAL THERAPY

Phebra has congratulated the lead project partner Clarity Pharmaceuticals after they received a $2.5 million grant from the Australian Government for further research and commercial development of their innovative radiopharmaceutical therapies which can target childhood cancers.

The grant, delivered under the Australian Government’s Cooperative Research Centres Programme (CRC-P), will fund further product development and a study of Clarity’s lead asset SARTATE™ in Neuroblastoma, a rare cancer, affecting about 40 children a year in Australia.

Clarity, in collaboration with the Australian Nuclear Science and Technology Organisation (ANSTO), Melbourne University and the Peter MacCallum Cancer Centre, has developed its proprietary SAR Technology. In the first instance this new concept involves utilising two forms of radiolabelled and targeted Copper isotopes, Copper-64 and Copper-67. Copper-64 isotope can be used to diagnose and image tumours and Copper-67 isotope can target them for treatment.

Clarity says the funding will allow it to expand Australia’s capabilities and products focused on cancer therapy in paediatrics using this unique SAR Technology. Product development will take place at Centre for Advanced Imaging (CAI) at the University of Queensland, while Sydney-based Phebra will provide assistance and training in drug formulation, manufacturing, regulatory compliance and sales.

Welcoming the grant, Phebra’s Chief Executive Officer, Dr Mal Eutick, said today: “Phebra is excited to be partnering with other innovative companies and organisations such as Clarity on a project which will strengthen Australia’s ability in the development of commercial pharmaceutical products. We strongly believe that Clarity has an excellent product that will benefit many patients and we are pleased to be involved with them.”

“As an Australian company, we are committed to creating opportunities for innovative research programs which involve training our workforce of young, highly-skilled scientists, and helping them develop their I.P into advanced, local manufacturing to achieve significantly improved health outcomes in the treatment of serious disease like cancer.”

About Phebra

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, North America and parts of Europe.

At Phebra, we create critical medicines that save and improve lives.

About Clarity

Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.

www.claritypharmaceuticals.com

Media contact: Richard Lenarduzzi

The Premier Communications Group 0411 254 390